CING Live signals | Maximize Profits with Getagraph.com

SELL 94234 min ago

@ $1.240

Issued: 13 Feb 2024 @ 09:47

Return: -29.03%

Previous signal: Feb 9 - 10:37

Previous signal: Buy

Return: 7.63 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder...

Stats
Today's Volume	43 767.00
Average Volume	320 387
Market Cap	3.50M
EPS	$-5.94 ( 2024-04-05 )
Next earnings date	( $-2.20 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0110 (1.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Werth Peter J.	Buy	694 096	Common Stock
2024-04-11	Werth Peter J.	Buy	341 912	Common Stock
2024-04-11	Werth Peter J.	Sell	694 096	Pre-Funded Warrant (right to buy)
2024-04-11	Werth Peter J.	Sell	341 912	Pre-Funded Warrant (right to buy)
2024-03-29	Silva Raul R.	Buy	1 000	Stock Option (right to Buy)

INSIDER POWER
77.44
Last 96 transactions
Buy: 11 671 641 \| Sell: 1 062 040

Volume Correlation

Long: -0.12 (neutral)

Short: 0.82 (strong)

Signal:(50.414) Same movement expected

Cingulate Inc. Correlation

10 Most Positive Correlations
ADXN	0.805

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cingulate Inc. Correlation - Currency/Commodity

0.43
( neutral )

0.74
( moderate )

0.00
( neutral )

-0.22
( neutral )

Cingulate Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-582 918 (0.00 %)
EPS:	$-26.00

Q4	2023
Revenue:	$0
Gross Profit:	$-172 325 (0.00 %)
EPS:	$-5.94

Q3	2023
Revenue:	$0
Gross Profit:	$-5.75M (0.00 %)
EPS:	$-6.05

Q2	2023
Revenue:	$0
Gross Profit:	$-6.36B (0.00 %)
EPS:	$-11.31

Financial Reports:

No articles found.

Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.